SCHEMBL2962976

SCHEMBL2962976

CCCc1ccc2c(Nc3cc(C)ccc3Sc3ccc(CO)cc3)ccnc2n1

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.35
MAPT P10636 2/20 0.35
KDM4E B2RXH2 1/20 0.34
PIM1 P11309 1/20 0.34
AKT2 P31751 1/20 0.34
TP53 P04637 2/20 0.33
LMNA P02545 2/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
HTR1A P08908 3/20 0.32
ADRA1D P25100 3/20 0.32
ADRA1A P35348 3/20 0.32
ADRA1B P35368 3/20 0.32
SREBF2 Q12772 1/20 0.32
ATM Q13315 1/20 0.31
L3MBTL1 Q9Y468 1/20 0.31
BLM P54132 2/20 0.31
HPGD P15428 1/20 0.31
MEN1 O00255 1/20 0.30
KMT2A Q03164 1/20 0.30
MAP2K4 P45985 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2961869 0.90 PIM1 (0.42) ALDH1A1MAPTKDM4EPIM1AKT2
SCHEMBL2970865 0.89 SREBF2 (0.36) ALDH1A1MAPTKDM4EPIM1AKT2
SCHEMBL2961431 0.88 PIM1 (0.36) ALDH1A1MAPTKDM4EPIM1AKT2
SCHEMBL2968588 0.87 SREBF2 (0.38) MAPTKDM4EPIM1AKT2TP53
SCHEMBL2019101 0.87 HTR1A (0.33) ALDH1A1MAPTKDM4EPIM1AKT2
SCHEMBL2961153 0.86 SREBF2 (0.44) ALDH1A1MAPTKDM4ETP53LMNA
SCHEMBL2969119 0.85 KDM4E (0.40) ALDH1A1MAPTKDM4EPIM1AKT2
SCHEMBL2965230 0.84 SREBF2 (0.37) ALDH1A1MAPTKDM4EPIM1AKT2
SCHEMBL2968113 0.83 KDM4E (0.35) ALDH1A1KDM4EPIM1AKT2LMNA
SCHEMBL2019804 0.82 PIM1 (0.41) MAPTKDM4EPIM1AKT2SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8338605-B2 Anti-viral compounds ABBOTT LABORATORIES (US) 2012-12-25 US disclosed
US-20100256139-A1 Anti-Viral Compounds ABBOTT LABORATORIES (US) 2010-10-07 US disclosed
EP-1979349-B1 ANTI-VIRAL COMPOUNDS ABBOTT LAB (US) 2010-07-28 EP disclosed
US-7763731-B2 Anti-viral compounds ABBOTT LABORATORIES (US) 2010-07-27 US disclosed
EP-1979349-A2 ANTI-VIRAL COMPOUNDS Abbott Laboratories (US) 2008-10-15 EP disclosed
US-20070232645-A1 ANTI-VIRAL COMPOUNDS ABBVIE INC. 2007-10-04 US disclosed
WO-2007076035-A2 ANTI-VIRAL COMPOUNDS ABBOTT LABORATORIES (US) 2007-07-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070232645-A1 ANTI-VIRAL COMPOUNDS HAVCR2, MAVS, EIF2AK2 ALDH1A1 2723/4885MAPT 1347/4885KDM4E 1822/4885
US-20100256139-A1 Anti-Viral Compounds HAVCR2, MAVS, EIF2AK2 ALDH1A1 2723/4885MAPT 1347/4885KDM4E 1822/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.